Akebia Therapeutics
AKBA
65 hedge funds and large institutions have $30.9M invested in Akebia Therapeutics in 2023 Q1 according to their latest regulatory filings, with 8 funds opening new positions, 15 increasing their positions, 15 reducing their positions, and 16 closing their positions.
475% more call options, than puts
Call options by funds: $466K | Put options by funds: $81K
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0% more repeat investments, than reductions
Existing positions increased: 15 | Existing positions reduced: 15
0% less capital invested
Capital invested by funds: $30.9M → $30.9M (-$36.1K)
0.2% less ownership
Funds ownership: 28.41% → 28.21% (-0.2%)
13% less funds holding
Funds holding: 75 → 65 (-10)
50% less first-time investments, than exits
New positions opened: 8 | Existing positions closed: 16
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$972K |
| 2 |
AIM
Alerce Investment Management
Chicago,
Illinois
|
+$852K |
| 3 |
Morgan Stanley
New York
|
+$231K |
| 4 |
Victory Capital Management
San Antonio,
Texas
|
+$182K |
| 5 |
Connor, Clark & Lunn Investment Management (CC&L)
Vancouver,
British Columbia, Canada
|
+$140K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
OCM
Ovata Capital Management
Hong Kong
|
-$767K |
| 2 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
-$623K |
| 3 |
Renaissance Technologies
New York
|
-$418K |
| 4 |
Jane Street
New York
|
-$365K |
| 5 |
Millennium Management
New York
|
-$330K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
USCWA
76
U.S. Capital Wealth Advisors
Austin,
Texas
| – | -$1.08K | -1,871 | Closed |
|
|
EWA
77
EverSource Wealth Advisors
Birmingham,
Alabama
| – | -$721 | -1,250 | Closed |
|
78
Northwestern Mutual Wealth Management
Milwaukee,
Wisconsin
| – | -$216 | -374 | Closed |
|
79
Belvedere Trading
Chicago,
Illinois
| – | -$58 | -100 | Closed |
|
|
CS
80
Credit Suisse
Zurich,
Switzerland
| – | -$3 | -5 | Closed |
|
AKBA Hedge Fund Activity: Q1 2023 in Review
65 of the 6,275 institutional investors tracked by Wall St. Rank reported a position in Akebia Therapeutics (AKBA) for Q1 2023, worth a combined $30.9M — down 0.12% from $30.9M a quarter earlier.
Sellers outnumbered buyers: 16 funds closed out of AKBA and 8 opened new positions — a net loss of 8 holders — while 15 trimmed existing stakes and 15 added.
The largest buyer was Vanguard Group, adding an estimated $972K. The largest seller was Ovata Capital Management, exiting entirely with an estimated $767K sold.
- 65 institutional investors held Akebia Therapeutics (AKBA) as of Q1 2023, down from 75 in Q4 2022.
- Funds reported $30.9M of Akebia Therapeutics stock for Q1 2023, down 0.12% quarter-over-quarter.
- 8 funds opened new Akebia Therapeutics positions in Q1 2023 and 16 closed out, a net change of -8 holders.
- The largest Akebia Therapeutics buyer in Q1 2023 was Vanguard Group, an estimated $972K added.
- The largest Akebia Therapeutics seller in Q1 2023 was Ovata Capital Management, an estimated $767K sold.
Based on aggregated 13F filings for Q1 2023.